tbuckley/cabot-search huggingface dataset:
Association between the use of statins and risk of interstitial lung disease/idiopathic pulmonary fibrosis: time-dependent analysis of population-based nationwide data
Authors: Hye Jin Jang, Dong Yoon Lee, Gjustina Loloci, Jihyeon Jeong, Won-Il Choi
Journal: European Respiratory Journal (2023)

Background We aimed to study whether statin use is associated with lowering the development of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). Methods The study population was the Korean National Health Insurance Service-Health Screening Cohort. ILD and IPF cases were identified using diagnosis codes (J84.1 for ILD and J84.1A as a special code for IPF) based on the International Classification of Diseases, 10th Revision. The study participants were followed up from 1 January 2004 to 31 December 2015. Statin use was defined by the cumulative defined daily dose (cDDD) per 2-year interval and participants were categorised into never-users, &lt;182.5, 182.5–365.0, 365.0–547.5 and ≥547.5 by cDDD. A Cox regression was used to fit models with time-dependent variables of statin use. Results Incidence rates for ILD with and without statin use were 20.0 and 44.8 per 100 000 person-years, respectively, and those for IPF were 15.6 and 19.3 per 100 000 person-years, respectively. The use of statins was independently associated with a lower incidence of ILD and IPF in a dose–response manner (p-values for trend &lt;0.001). ILD showed respective adjusted hazard ratios (aHRs) of 1.02 (95% CI 0.87–1.20), 0.60 (95% CI 0.47–0.77), 0.27 (95% CI 0.16–0.45) and 0.24 (95% CI 0.13–0.42) according to the increasing category of statin use compared with never-users. IPF showed respective aHRs of 1.29 (95% CI 1.07–1.57), 0.74 (95% CI 0.57–0.96), 0.40 (95% CI 0.25–0.64) and 0.21 (95% CI 0.11–0.41). Conclusion A population-based cohort analysis found that statin use is independently associated with a decreased risk of ILD and IPF in a dose–response manner.
Developing a pan-European technical standard for a comprehensive high-quality lung cancer computed tomography screening programme: an ERS technical standard
Authors: David R. Baldwin, Emma L. O'Dowd, Ilona Tietzova, Anna Kerpel-Fronius, Marjolein A. Heuvelmans, Annemiek Snoeckx, Haseem Ashraf, Hans-Ulrich Kauczor, Blin Nagavci, Matthijs Oudkerk, Paul Martin Putora, Witold Ryzman, Giulia Veronesi, Andrea Borondy-Kitts, Antoni Rosell Gratacos, Jan van Meerbeeck, Torsten G. Blum
Journal: European Respiratory Journal (2023)

Screening for lung cancer with low radiation dose computed tomography (LDCT) has a strong evidence base. The European Council adopted a recommendation in November 2022 that lung cancer screening be implemented using a stepwise approach. The imperative now is to ensure that implementation follows an evidence-based process that delivers clinical and cost effectiveness. This ERS Taskforce was formed to provide a technical standard for a high-quality lung cancer screening program.A collaborative group was convened to include members of multiple European societies (see below). Topics were identified during a scoping review and a systematic review of the literature was conducted. Full text was provided to members of the group for each topic. The final document was approved by all members and the ERS Scientific Advisory Committee.Ten topics were identified representing key components of a screening program. The action on findings from the LDCT were not included as they are addressed by separate international guidelines (nodule management and clinical management of lung cancer) and by a linked taskforce (incidental findings). Other than smoking cessation, other interventions that are not part of the core screening process were not included (e.g. pulmonary function measurement). Fifty-three statements were produced and areas for further research identified.This European collaborative group has produced a technical standard that is a timely contribution to implementation of LCS. It will serve as a standard that can be used, as recommended by the European Council, to ensure a high quality and effective program.
Lincoln Sign in a Case of Primary Hyperparathyroidism on 18F-Fluorocholine PET/CT
Authors: Sneha Prakash, Nishikant Avinash Damle, Praveen Kumar, Yamini Dharmashaktu, C.S. Bal
Journal: Clinical Nuclear Medicine (2023)

Lincoln sign or black beard sign is one of the signs that have been classically described on bone scintigraphy in monostotic Paget disease, when mandible is involved. Extensive involvement of the mandible causes increased radiotracer uptake from one mandibular condyle to the other, resembling a black beard. We present the case of a 14-year-old girl with primary hyperparathyroidism who underwent an 18 F-fluorocholine PE/CT to locate the parathyroid adenoma. MIP image of the PET/CT incidentally showed black beard sign due to increased radiotracer uptake in the mandible.
Incidence of interstitial lung abnormalities: the MESA Lung Study
Authors: Claire F. McGroder, Spencer Hansen, Karen Hinckley Stukovsky, David Zhang, P. Hrudaya Nath, Mary M. Salvatore, Sushilkumar K. Sonavane, Nina Terry, Justin T. Stowell, Belinda M. D'Souza, Jay S. Leb, Shifali Dumeer, Muhammad U. Aziz, Kiran Batra, Eric A. Hoffman, Elana J. Bernstein, John S. Kim, Anna J. Podolanczuk, Jerome I. Rotter, Ani W. Manichaikul, Stephen S. Rich, David J. Lederer, R. Graham Barr, Robyn L. McClelland, Christine Kim Garcia
Journal: European Respiratory Journal (2023)

Background The incidence of newly developed interstitial lung abnormalities (ILA) and fibrotic ILA has not been previously reported. Methods Trained thoracic radiologists evaluated 13 944 cardiac computed tomography scans for the presence of ILA in 6197 Multi-Ethnic Study of Atherosclerosis (MESA) longitudinal cohort study participants &gt;45 years of age from 2000 to 2012. Five percent of the scans were re-read by the same or a different observer in a blinded fashion. After exclusion of participants with ILA at baseline, incidence rates and incidence rate ratios for ILA and fibrotic ILA were calculated. Results The intra-reader agreement of ILA was 92.0% (Gwet's AC1 0.912, intraclass correlation coefficient (ICC) 0.982) and the inter-reader agreement of ILA was 83.5% (Gwet's AC1 0.814, ICC 0.969). Incidence of ILA and fibrotic ILA was estimated to be 13.1 and 3.5 cases per 1000 person-years, respectively. In multivariable analyses, age (hazard ratio (HR) 1.06 (95% CI 1.05–1.08); p&lt;0.001 and HR 1.08 (95% CI 1.06–1.11); p&lt;0.001), high attenuation area at baseline (HR 1.05 (95% CI 1.03–1.07); p&lt;0.001 and HR 1.06 (95% CI 1.02–1.10); p=0.002) and the MUC5B promoter single nucleotide polymorphism (HR 1.73 (95% CI 1.17–2.56); p=0.01 and HR 4.96 (95% CI 2.68–9.15); p&lt;0.001) were associated with incident ILA and fibrotic ILA, respectively. Ever-smoking (HR 2.31 (95% CI 1.34–3.96); p=0.002) and an idiopathic pulmonary fibrosis polygenic risk score (HR 2.09 (95% CI 1.61–2.71); p&lt;0.001) were associated only with incident fibrotic ILA. Conclusions Incident ILA and fibrotic ILA were estimated by review of cardiac imaging studies. These findings may lead to wider application of a screening tool for atherosclerosis to identify pre-clinical lung disease.
Transforming growth factor-β2 is associated with atherosclerotic plaque stability and lower risk for cardiovascular events
Authors: Andreas Edsfeldt, Pratibha Singh, Frank Matthes, Christoffer Tengryd, Michele Cavalera, Eva Bengtsson, Pontus Dunér, Petr Volkov, Glykeria Karadimou, Anton Gisterå, Marju Orho-Melander, Jan Nilsson, Jiangming Sun, Isabel Gonçalves
Journal: Cardiovascular Research (2023)

Abstract Aims Transforming growth factor-beta (TGF-β) exists in three isoforms TGF-β1, -β2, and -β3. TGF-β1 has been suggested to be important for maintaining plaque stability, yet the role of TGF-β2 and -β3 in atherosclerosis remains to be investigated. This study explores the association of the three isoforms of TGF-β with plaque stability in the human atherosclerotic disease. Methods and results TGF-β1, -β2, and -β3 proteins were quantified in 223 human carotid plaques by immunoassays. Indications for the endarterectomy were: symptomatic carotid plaque with stenosis &amp;gt;70% or without symptoms and &amp;gt;80% stenosis. Plaque mRNA levels were assessed by RNA sequencing. Plaque components and extracellular matrix were measured histologically and biochemically. Matrix metalloproteinases and monocyte chemoattractant protein-1 (MCP-1) was measured with immunoassays. The effect of TGF-β2 on inflammation and protease activity was investigated in vitro using THP-1 and RAW264.7 macrophages. Patients were followed longitudinally for cardiovascular (CV) events. TGF-β2 was the most abundant isoform and was increased at both protein and mRNA levels in asymptomatic plaques. TGF-β2 was the main determinant separating asymptomatic plaques in an Orthogonal Projections to Latent Structures Discriminant Analysis. TGF-β2 correlated positively to features of plaque stability and inversely to markers of plaque vulnerability. TGF-β2 was the only isoform inversely correlated to the matrix-degrading matrix metalloproteinase-9 and inflammation in the plaque tissue. In vitro, TGF-β2 pre-treatment reduced MCP-1 gene and protein levels as well as matrix metalloproteinase-9 gene levels and activity. Patients with plaques with high TGF-β2 levels had a lower risk to suffer from future CV events. Conclusions TGF-β2 is the most abundant TGF-β isoform in human plaques and may maintain plaque stability by decreasing inflammation and matrix degradation.
FDG PET/CT Findings of Malignant Rhabdoid Tumor Arising From a Renal Allograft
Authors: Zhengguang Xiao, Wenjie Lu, Aisheng Dong, Yang Wang
Journal: Clinical Nuclear Medicine (2023)

Malignant rhabdoid tumor of the kidney is a rare aggressive malignancy with poor prognosis. We describe FDG PET/CT findings in a case of malignant rhabdoid tumor of the renal allograft with regional lymph node and pulmonary metastases. The primary renal tumor and lymph node metastases showed intense FDG uptake. The pulmonary metastases showed minimal FDG uptake due to small size. Posttreatment FDG PET/CT showed no evidence of residual disease. This case suggests that FDG PET/CT may be useful in the management of malignant rhabdoid tumor from the transplanted kidney.
3D-Ring CZT System With New Low- and Medium-Energy Range
Authors: Aurélien Callaud, Gilles Metrard, Matthieu Bailly
Journal: Clinical Nuclear Medicine (2023)

New 3D-ring CZT systems with low- and medium-energy-range detectors allow for simultaneous dual-isotope lung scintigraphy. We compared 10-, 7-, 5-, and 3-minute acquisitions for 99m Tc and 81m Kr performed simultaneously on StarGuide CZT-SPECT/CT and reframed in 50 patients. Ventilation/perfusion mismatches were calculated (mean, 15.6% ± 28%), and Spearman correlation coefficients of mismatches were 0.994, 0.994, and 0.984 between 10- and 7-, 5-, and 3-minute acquisitions, respectively. No visual difference in image quality or final diagnosis was found. 3D-ring CZT-SPECT with low and medium energy range detectors allows ultrafast dual-isotope lung scintigraphy up to 3 minutes.
Research priorities in the management of hidradenitis suppurativa
Authors: Paul Leighton, Laura Howells, Janine Bates, Angela Gibbons, Rebecca Cannings-John, Fiona Collier, Judith Evans, Ceri Harris, Kerry Hood, Rachel Howes, Muhammad Riaz, Jeremy Rodrigues, Helen Stanton, Emma Thomas-Jones, Kim Thomas, John R Ingram
Journal: British Journal of Dermatology (2023)

There is a need for high-quality research to support the management of hidradenitis suppurativa. This letter offers suggestions for priority research topics derived from a stakeholder consensus meeting. Investigation of laser hair removal treatment, potentially in combination with medical treatment, was recognized as an important focus for future hidradenitis suppurativa research.
Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study
Authors: Ryan W Huey, Aakash Tushar Shah, Honey V Reddi, Priyadarsini Dasari, James T Topham, Hyunsoo Hwang, Nishat Dhillon, Anneleis Willett, Brandon G Smaglo, Jeannelyn S Estrella, Asif Rashid, Aurelio Matamoros, Michael J Overman, Linda Choquette, Greg Omerza, Kevin Kelly, Xuemei Wang, Jonathan M Loree, Jens Rueter, Gauri R Varadhachary, Kanwal Raghav
Journal: JNCI Journal of the National Cancer Institute (2023)

Abstract Real-world evidence regarding the value of integrating genomic profiling (GP) in managing cancer of unknown primary (CUP) is limited. We assessed this clinical utility using a prospective trial of 158 patients with CUP (October 2016-September 2019) who underwent GP using next-generation sequencing designed to identify genomic alterations (GAs). Only 61 (38.6%) patients had sufficient tissue for successful profiling. GAs were seen in 55 (90.2%) patients of which GAs with US Food and Drug Administration–approved genomically matched therapy were seen in 25 (40.9%) patients. A change in therapy was recommended and implemented (primary endpoint of the study) in 16 (10.1%) and 4 (2.5%) patients of the entire study cohort, respectively. The most common reason for inability to implement the profiling-guided therapy was worsening of performance status (56.3%). Integrating GP in management of CUP is feasible but challenging because of paucity of tissue and aggressive natural history of the disease and requires innovative precision strategies.
Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias
Authors: Eugene Nikitin, Maria Kislova, Dmitry Morozov, Vera Belyakova, Anna Suvorova, Julia Sveshnikova, Galina Vyscub, Irina Matveeva, Maria Shirokova, Anna Shipaeva, Tatyana Klitochenko, Polina Makarovskaya, Elena Dmitrieva, Bella Biderman, Andrei Sudarikov, Tatyana Obukhova, Olga Samoilova, Kamil Kaplanov, Tatyana Konstantinova, Olga Mayorova, Irina Poddubnaya, Vadim Ptushkin
Journal: Leukemia (2023)
Individualized Family Screening for Arrhythmogenic Right Ventricular Cardiomyopathy
Authors: Steven A. Muller, Alessio Gasperetti, Laurens P. Bosman, Amand F. Schmidt, Annette F. Baas, Ahmad S. Amin, Arjan C. Houweling, Arthur A.M. Wilde, Paolo Compagnucci, Mattia Targetti, Michela Casella, Leonardo Calò, Claudio Tondo, Pim van der Harst, Folkert W. Asselbergs, J. Peter van Tintelen, Marish I.F.J. Oerlemans, Anneline S.J.M. te Riele
Journal: Journal of the American College of Cardiology (2023)
Incidence, Treatment, and Outcomes of Symptomatic Device Lead-Related Venous Obstruction
Authors: Enrico G. Ferro, Daniel B. Kramer, Siling Li, Andrew H. Locke, Shantum Misra, Alec A. Schmaier, Brett J. Carroll, Yang Song, Andre A. D’Avila, Robert W. Yeh, Peter J. Zimetbaum, Eric A. Secemsky
Journal: Journal of the American College of Cardiology (2023)
Tanzania's COVID-19 vaccination strategy: lessons, learning, and execution
Authors: Sayoki Godfrey Mfinanga, Wangeci Gatei, Florian Tinuga, William Mngupe Patrick Mwengee, Zabulon Yoti, Ntuli Kapologwe, Tumaini Nagu, Maheshi Swaminathan, Abel Makubi
Journal: The Lancet (2023)
Airway dysbiosis accelerates lung function decline in chronic obstructive pulmonary disease
Authors: Weijie Liang, Yuqiong Yang, Shenhai Gong, Mingyuan Wei, Yingfei Ma, Ruipei Feng, Jingyuan Gao, Xiaomin Liu, Fuyi Tu, Wei Ma, Xinzhu Yi, Zhenyu Liang, Fengyan Wang, Lingwei Wang, Dandan Chen, Wensheng Shu, Bruce E. Miller, Ruth Tal-Singer, Gavin C. Donaldson, Jadwiga A. Wedzicha, Dave Singh, Tom M.A. Wilkinson, Christopher E. Brightling, Rongchang Chen, Nanshan Zhong, Zhang Wang
Journal: Cell Host & Microbe (2023)
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial
Authors: Erin Furr Stimming, Daniel O Claassen, Elise Kayson, Jody Goldstein, Raja Mehanna, Hui Zhang, Grace S Liang, Dietrich Haubenberger, Jamie Adams, Christopher Beck, Cheryl Chen, Martha Nance, Claudia Testa, Patricia Huffman, Amy Chesire, Frederick Marshall, Praveen Dayalu, Angela Stovall, Deborah Hall, Jacob Hawkins, Letty Ginsburg, Henry Moore, Tiago Mestre, Tanya Thompson, Natalie Connors, H. Diana Rosas, Allison Daley, Sandra K. Kostyk, Casey Mitchell, Amy Hellman, Sheryl Houston, Danielle Buchanan, Katherine McDonell, Stewart A. Factor, Elaine Sperin, Andrea Hurt, Joanne Wojcieszek, Mike Adurogbangba, Lynn A. Raymond, Jody Corey-Bloom, Chase Snell, Courtney Blair, Victor Sung, Sophia Antonioli, Jacqueline Fung, Simon Laganiere, Luis Sierra, William M. Mallonee, Greg Suter, Danny Bega, Zsa Zsa Brown, Lawrence Elmer, Nancy Vollmar, Debra del Castillo, Yi-Han Lin, Kelly Andrzejewski, Patricia Weigel, Trevor Hawkins, Kendra Kirby, Cimmaron Retzik-Stahr, Lauren Seeberger, Rohit Dhall, Anja Rassmann, McKenzie Luxmore, Burton Scott, Bisena Bulica, James Boyd, Katherine Chan, Nikolaus McFarland, Kyle Rizer, Patricia Conlon, Valerie Suski, Federico Rodriguez-Porcel, Sandra Wilson, Christine Farrell, David Hunter, David Houghton, Sarah Seoane, Clare Gibbons, Philippe Rizek, Robin Kuprewicz, Steven Lo, Miroslav Cuturic, Vicki Segro, Kate Greenly, Fredy Revilla, Enrique Urrea-Mendoza, Kevin J. Black, Thomas Davis, Natividad Stover, Andrew Duker, Jay Van Gerpen, Peter Hedera, William Ondo, Karen Anderson, Stephen Bradley, Ken Cheung, Samuel Frank
Journal: The Lancet Neurology (2023)
Stem cell-derived hepatocyte therapy using versatile biomimetic nanozyme incorporated nanofiber-reinforced decellularized extracellular matrix hydrogels for the treatment of acute liver failure
Authors: Yuanyuan Jin, Jiabin Zhang, Yanteng Xu, Ke Yi, Fenfang Li, Huicong Zhou, Haixia Wang, Hon Fai Chan, Yeh-Hsing Lao, Shixian Lv, Yu Tao, Mingqiang Li
Journal: Bioactive Materials (2023)

Reactive oxygen species (ROS)-associated oxidative stress, inflammation storm, and massive hepatocyte necrosis are the typical manifestations of acute liver failure (ALF), therefore specific therapeutic interventions are essential for the devastating disease. Here, we developed a platform consisting of versatile biomimetic copper oxide nanozymes (Cu NZs)-loaded PLGA nanofibers (Cu [email protected] nanofibers) and decellularized extracellular matrix (dECM) hydrogels for delivery of human adipose-derived mesenchymal stem/stromal cells-derived hepatocyte-like cells (hADMSCs-derived HLCs) (HLCs/Cu [email protected]/dECM). Cu [email protected] nanofibers could conspicuously scavenge excessive ROS at the early stage of ALF, and reduce the massive accumulation of pro-inflammatory cytokines, herein efficiently preventing the deterioration of hepatocytes necrosis. Moreover, Cu [email protected] nanofibers also exhibited a cytoprotection effect on the transplanted HLCs. Meanwhile, HLCs with hepatic-specific biofunctions and anti-inflammatory activity acted as a promising alternative cell source for ALF therapy. The dECM hydrogels further provided the desirable 3D environment and favorably improved the hepatic functions of HLCs. In addition, the pro-angiogenesis activity of Cu [email protected] nanofibers also facilitated the integration of the whole implant with the host liver. Hence, HLCs/Cu [email protected]/dECM performed excellent synergistic therapeutic efficacy on ALF mice. This strategy using Cu [email protected] nanofiber-reinforced dECM hydrogels for HLCs in situ delivery is a promising approach for ALF therapy and shows great potential for clinical translation.
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial
Authors: Shengyuan Yu, Byung-Kun Kim, Aihong Guo, Man-Ho Kim, Mingjie Zhang, Zhen Wang, Jianguang Liu, Heui-Soo Moon, Ge Tan, Qian Yang, Donnie McGrath, Michael Hanna, David A Stock, Yanfei Gao, Robert Croop, Zhihong Lu
Journal: The Lancet Neurology (2023)
The Brain Research Africa Initiative (BRAIN)
Authors: Alfred K Njamnshi, Leonard Ngarka, Wepnyu Y Njamnshi, Nene Ahidjo, Joelle N Chabwine, Vladimir Hachinski, Nene Ahidjo, Jean Marie Annoni, Joelle Nsimire Chabwine, Vladimir Hachinski, Leonard Ngarka, Alfred Kongnyu Njamnshi, Wepnyu Yembe Njamnshi, Stephen Perrig, Roman Sztajzel
Journal: The Lancet Neurology (2023)
Reply to “Smeltzer MP, Liao W, Faris NR, et al. Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening. J Thorac Oncol. 2023;18(2):158–168”
Authors: Natthaya Triphuridet, Sai-Hong Ignatius Ou
Journal: Journal of Thoracic Oncology (2023)
Response to a Letter Received Entitled: “‘Brief Report: Canadian Cancer Trials Group IND.227’: Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma”
Authors: Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, Lesley Seymour
Journal: Journal of Thoracic Oncology (2023)
Table of Contents
Authors: Lukas Delasos, Anant Madabhushi, Chao-Hua Chiu, Pan-Chyr Yang, Michele Carbone, Haining Yang, Harvey Pass, Emanuela Taioli, Natthaya Triphuridet, Shannon Zhang, Misako Nagasaka, Yanfei Gao, Joseph Zhao, Nicholas Syn, Takaomi Hanaoka, Sai-Hong Ou, Elaine Shum
Journal: Journal of Thoracic Oncology (2023)
In vitro and in vivo degradation behavior of Mg-0.45Zn-0.45Ca (ZX00) screws for orthopedic applications
Authors: Diana C. Martinez, Anna Dobkowska, Romy Marek, Hanna Ćwieka, Jakub Jaroszewicz, Tomasz Płociński, Črtomir Donik, Heike Helmholz, Bérengère Luthringer-Feyerabend, Berit Zeller-Plumhoff, Regine Willumeit-Römer, Wojciech Święszkowski
Journal: Bioactive Materials (2023)

Magnesium (Mg) alloys have become a potential material for orthopedic implants due to their unnecessary implant removal, biocompatibility, and mechanical integrity until fracture healing. This study examined the
Tom Nolan’s research reviews—18 May 2023
Authors: Tom Nolan
Journal: BMJ (2023)

Out-of-office remindersChecking blood pressure using a 24 hour blood pressure monitor is referred to as out-of-office blood pressure in the US.According to a new study in the Lancet, it seems that, when it comes to diagnosis and monitoring of hypertension, we should keep the out-of-office on.The observational cohort study of a registry of over 50 000 patients in Spain compared blood pressure measured in a clinic with out-of-office blood pressure and each method's association with all-cause and cardiovascular death over a median 9.7 year follow-up period.The 24 hour blood pressure measurements more closely correlated with all-cause mortality than clinic blood pressure-although a linked editorial asks whether some of the difference may reflect the quality of measurements performed in clinics.